Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences plans to launch Semaglutide Injection (15 mg/3 ml) in India on the first day of the drug's patent expiry, under three brand names: SEMAGLYN, MASHEMA, and ALTERME. The drug has already received approval from India's drug regulator (DCGI) for treating Type 2 Diabetes and Obesity. Zydus has developed a unique, indigenously-built adjustable single-pen device that lets patients select and administer multiple dose strengths from one reusable pen, unlike existing treatments that require buying several single-dose pens. The company holds exclusive rights to this novel delivery system for all approved strengths. The move targets India's large GLP-1 therapy market, where 8.9 crore adults (10.5% of the adult population) live with diabetes and obesity rates have nearly doubled in both men and women in recent years.
This positions Zydus as a first-mover in the Indian Semaglutide market with a differentiated, cost-friendly delivery device, which could drive significant revenue growth and strengthen its share in the fast-expanding diabetes and obesity segment. Investors may view this positively given the large addressable market and the company's exclusive hold on the pen technology.